The DFA Discussion, page-47

@FreeFromStyle don’t be too hard on yourself, the DFA investors are very very sophisticated Biotech investors (and equity investors) with (according to the entities websites) circa 96 or so FDA approved medicines they have helped to establish.
In addition Regal also professional & sophisticated. The Ph3 in this specific combo was different to what these sophisticated investors & the scientists supporting OPT anticipated.

Firstly Soz in combo in this trial was different to the Ph2B trial. The combo medicine was different to the Ph2B.

Shore may still indicate efficacy